Emcure Pharma
Emcure Pharma Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
The short version
Emcure expects low to mid-teen revenue growth for FY27 with positive movement quarter-over-quarter. Emcure expects low to mid-teen revenue growth in FY27, indicating steady top-line expansion.
From Emcure Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Emcure expects low to mid-teen revenue growth for FY27 with positive movement quarter-over-quarter.
- Domestic business growth is anticipated to improve from current levels, targeting to be in line with or faster than industry growth from Q2 onward.
- Organic domestic growth guided at 6%-8%, with acceleration expected in the second half of FY27.
- International business, especially Europe, Canada, and Rest of World markets, poised for solid growth supported by new launches, strong approval pipeline, and differentiated products.
- ARV and non-ARV segments in international markets expected to contribute roughly equally (~50:50) over the full year.
- R&D expenses will increase, maintaining around 4%-5% of revenues to support innovation and growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Emcure Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company expects R&D expenses to increase, maintaining an outlook of 4% to 5% of revenue for FY27, indicating strategic investment in product development.
- They continue to focus on building differentiated capabilities in biologics, complex injectables, and novel delivery systems, particularly liposomal technology.
- Recent technology transfer initiatives include licensing a novel anti-HPV candidate from ICMR, part of women's health R&D pipeline.
- Entered a royalty-free licensing agreement with MSD to manufacture a generic oral HIV pill for low and lower-middle income countries, strengthening their ARV portfolio.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Emcure Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Emcure is ramping up supplies across different countries, leading to an increase in the order book in line with supplies.
- The company sees good visibility on some order books, particularly in the ARV (antiretroviral) segment.
- The Rest of the World business growth is strongly supported by ARV and tender-based products with ongoing procurement cycles expected to pick up in coming quarters.
2 more points management made on order book & pipeline
Emcure Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.5K Cr, net profit ₹244 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Emcure Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Emcure Pharma Q1 FY27 results?
Emcure expects low to mid-teen revenue growth for FY27 with positive movement quarter-over-quarter. Emcure expects low to mid-teen revenue growth in FY27, indicating steady top-line expansion.
What is Emcure Pharma share price analysis?
Emcure Pharma currently shows a below-average growth signal. The stock trades at a P/E of 34.3 with a market cap of ₹35,337 Cr. Investors should review the full earnings analysis for detailed insights.
Is Emcure Pharma planning capital expenditure?
The company expects R&D expenses to increase, maintaining an outlook of 4% to 5% of revenue for FY27, indicating strategic investment in product development.
Keep Emcure Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.